-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BMS
signed a five-year cooperation agreement with Machine Learning specialist Intro to develop drugs for the treatment of amyotrophic lateral sclerosis (ALS) and alzheimer's disease.Under the agreement, BMS will make an advance payment of $50 million to Intro, and Insitro will be eligible for an additional $20 million in recent business milestones, as well as
's further milestones of more than $2 billion
and sales royalties.Insitro will use its novel platform to develop disease models derived from induced popotent stem cells (iPSCs) for ALS and frontal temporal lobe dementia to identify candidate targets.The platform applies machine learning, human genetics, and functional genomics to generate and optimize in-body predictive models and help identify and develop treatments.
, BMS will be able to select a number of objectives to advance clinical development and will also be responsible for regulatory submission and ultimately commercial activities."We believe machine learning and data generated by the new experimental platform provides an opportunity to rethink how we discover and design new drugs," said Richard Hargreaves, senior vice president of research and early development at BMS Neuroscience TRC.
The current medical needs for treatments for ALS and FTD have not been met, and we are excited about the prospect of working with the Insitro team to achieve our common goal of identifying conversion therapies for patients with these devastating diseases." (cyy123.com)original source: